| Main Article
| Discussion
| Related Articles  [?]
| Bibliography  [?]
| External Links  [?]
| Citable Version  [?]

|
|
|
|
|
|
|
|

This editable Main Article is under development and subject to a disclaimer.

[edit intro]

A monoclonal antibody is an immune substance "produced by clones of cells such as those isolated after hybridization of activated B-lymphocytes with neoplastic cells. These hybrids are often referred to as hybridomas." [1] Monoclonal antibodies have extensive applications in clinical medicine and immunochemistry.

The World Health Organization is refining naming conventions for monoclonal antibodies. [2] Its original system came from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group.[3]

Naming of monoclonal antibodies is governed by World Health Organization’s International Nonproprietary Name (INN):

* Human monoclonal antibody. INN names end in -umab. Example is olaratumab.
* Humanized monoclonal antibody. INN names end in -zumab. Example is benralizumab.
* Chimeric monoclonal antibody. INN names end in -ximab. Example is rituximab.

## References[edit]

1. ↑ Anonymous (2022), Antibody, monoclonal (English). Medical Subject Headings. U.S. National Library of Medicine.
2. ↑ Anna-Maija Autere, Nicole Wagner and Georg-Burkhard Kresse from Roche on behalf of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group (2008), "International Nonproprietary Names for monoclonal antibodies: IFPMA proposal", WHO Drug Information 22 (2), pp. 97-107
3. ↑ International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group (2008), [http://www.ifpma.org/fileadmin/templates/ifpmaissues/pdfs/2008_03_21_IFPMA_Proposal_for_naming_of_new_monoclonals.pdf Proposal to the WHO INN Expert Group: Principles for naming of new monoclonal antibodies]